fighting-tigers
30 April 2014AsiaArchana Shanker

The Copaxone battle: an update

Copaxone (glatiramer acetate) is a blockbuster drug for the treatment of multiple sclerosis, created by Yeda Research and Development Co Ltd. The patents that cover Copaxone, including the process for its preparation, have been extensively litigated around the globe, and in India the patent for the preparation of Copaxone expires on May 23, 2015. For this process patent, several proceedings are currently pending before various bodies in India, including the Delhi High Court, the Intellectual Property Appellate Board and the Indian Patent Office (IPO).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
20 March 2026   As the patent protecting semaglutide—the drug that made Novo Nordisk one of Europe's most valuable companies—expires in ten countries, the pressure mounts for prices and market leaders alike.
Asia
5 February 2026   The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.
Asia
20 January 2026   Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.